Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.09% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Dec 31, 2023
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-038176General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-286.94% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-46.46% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
36.74% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
38.09% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-261.50% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
26.02% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
13.45% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.00%
- Current
- 0.09%
- Delta
- 0.09%
- Previous
- -180.65%
- Current
- -286.94%
- Delta
- -106.29%
- Previous
- -14.96%
- Current
- -46.46%
- Delta
- -31.50%
- Previous
- 166.37%
- Current
- 36.74%
- Delta
- -129.64%
- Previous
- 31.00%
- Current
- 38.09%
- Delta
- 7.09%
- Previous
- -203.01%
- Current
- -261.50%
- Delta
- -58.50%
- Previous
- 19.10%
- Current
- 26.02%
- Delta
- 6.92%
- Previous
- 10.14%
- Current
- 13.45%
- Delta
- 3.31%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA historical state 2024-03-31 →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA historical state 2023-09-30 →Transitioned To · RKDA CAPEX_INTENSITY_INCREASED →Transitioned To · RKDA CASH_GENERATION_DECREASED →Transitioned To · RKDA GROWTH_DECREASED →Transitioned To · RKDA INVENTORY_PRESSURE_DECREASED →Transitioned To · RKDA MARGIN_INCREASED →Transitioned To · RKDA PROFITABILITY_DECREASED →Transitioned To · RKDA R_AND_D_INTENSITY_INCREASED →Transitioned To · RKDA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.